Neuregulin 1 (NRG1), a ligand for HER3 and HER4 receptors, is secreted by both pancreatic tumor cells (PC) and cancer-associated fibroblasts (CAFs), the latter representing the most abundant compound of pancreatic stroma. This desmoplastic stroma contributes to Pancreatic Ductal Adenocarcinoma (PDAC) aggressiveness and therapeutic failure by promoting tumor progression, invasion and resistance to chemotherapies. In the present work, we aimed at disrupting the complex crosstalk between PC and CAF in order to prevent tumor cell proliferation. To do so, we demonstrated the promising tumor growth inhibitory effect of the 7E3, an original antibody directed to NRG1. This antibody promotes antibody dependent cellular cytotoxicity in NRG1-positive PC and CAFs and inhibits NRG1-associated signaling pathway induction, by blocking NRG1-mediated HER3 activation. Moreover, 7E3 inhibits migration and growth of pancreatic cancer cells co-cultured with CAFs, both in vitro and in vivo using orthotopic pancreatic tumor xenografts. Our preclinical results demonstrate that the anti-NRG1 antibody 7E3 could represent a promising approach to target pancreatic stroma and cancer cells, thereby providing novel therapeutic options for PDAC.
Pancreatic cancer remains one of the most aggressive tumors with an extremely poor prognosis and is estimated to become the second leading cause of cancer-related death by 2030 1, 2. This dramatic outcome is related to the lack of efficient therapeutic tools, early diagnostic markers, and high resistance to chemotherapy.
Abundant desmoplastic reaction is a prominent feature of pancreatic cancer and constitutes up to 80% of the total tumor volume. It is characterized by the presence mainly of cancer-associated fibroblasts (CAFs), but also of immune cells, vasculature, and extracellular matrix (ECM). These stroma characteristics contribute to pancreatic cancer aggressivity and therapeutic failure because they promote tumor progression, invasion and resistance to chemotherapies 3, 4. Once activated, CAFs express alpha smooth muscle actin (SMA) and secrete ECM and soluble factors (e.g., growth and inflammatory factors) that stimulate tumor growth and mediate inflammation. In preclinical studies, stroma disruption, by direct CAF targeting (hedgehog signaling inhibitors) 5 or by ECM enzymatic digestion (hyaluronidase), results in tumor inhibition and increases drug delivery 6; however, controversial or disappointing results were reported by clinical trials. Moreover, recent studies have questioned CAF role in pancreatic tumor maintenance and highlighted the need of caution when targeting CAFs 7-9. Indeed, several evidences indicate that there are different CAF subtypes with different functions 10, 11. Therefore, characterization of these subtypes is needed to enable the specific targeting of CAFs with pro-tumor features.
Neuregulins (NRGs) are large polypeptide growth factors that are part of the EGF family of proteins.
They are encoded by four genes (NRG1-4) that are subject to extensive alternative mRNA splicing, leading to more than 30 variants grouped in six types (I-VI) with a distinct N-terminal part. NRG1 and 2 are both HER3 and HER4 ligands and have at least two splice alternatives in their EGF-like domains, 
Disruption of intracellular communications between stromal and cancer cells could affect tumor
proliferation and represents an interesting therapeutic strategy. In this context, we hypothesized that targeting NRG, which we here show to be secreted both by CAFs and tumor cells, could be a novel therapy to overcome CAF-triggered tumor growth in pancreatic cancer. Here, we investigated, in in vivo and in vitro co-culture of pancreatic cancer cells and CAFs, the therapeutic potential of an original monoclonal antibody (7E3) that targets NRG1 Ig-like domain. We show promising tumor growth inhibitory effects of this antibody which promotes antibody dependent cellular cytotoxicity (ADCC) in NRG1-permeated pancreatic cancer cells and in NRG1-positive CAFs and blocks NRG1-mediated HER3 activation and downstream signaling pathway induction.
MATERIALS AND METHODS

Cell lines and reagents
The BxPC-3, CFPAC-1, HPAC, AsPC-1, SW1990, MiaPaCa-2 and MCF7 cancer cell lines were obtained from ATCC (Rockville, MD, USA) and cultured following the ATCC recommendations. The identity of cell lines was confirmed by genetics authentification test (Eurofins, Ebersberg). BxPC-3-Luc, HPAC-Luc, shHER3 BxPC-3 and shluc BxPC-3 cells were generated previously in the laboratory [23. Stably-transfected AsPC-1-Mock (vector alone) and AsPC-1-NRG1 cells were obtained as previously described for pMSCV-hygro-NRG1(OriGene) [24.
RhNRG11-ECD and HER3-Fc were purchased from RD Systems (Minneapolis, MN). All antibodies used in western blot were from Cell Signaling Technology (Beverly, MA). Antibodies against HER3
(16D3-C1) and CEA (35A7) were generated previously in the laboratory [25.
Human CAF isolation and cell culture
CAFs were isolated from human PDAC samples using the outgrowth method described by Duluc 
NRG1 secretion analysis
Conditioned medium were analyzed using the NRG1 1 human ELISA kit (Abcam) according the manufacturer instructions. Concentrations were calculated from standard curve and data are representative of two independent experiments.
Generation of monoclonal antibodies
BALB/c mice were immunized with 10 g rhNRG11-EDC by subcutaneous injection as described previously [25. Antibodies were produced by Biotem (Apprieu, France) and stored at -20°C in phosphate buffered saline (PBS).
2.6. Epitope mapping 213 overlapping dodecapeptides that were frame-shifted by one or three residues and that covered the entire amino acid sequence of human NRG1 ECD were synthesized on cellulose membrane and epitope mapping was performed as already described [23. For SPOT alanine scanning analysis, three pentadecapeptides corresponding to the identified antibody-immunoreactive sequences and the 13 alanine analogs of each peptide were synthesized by using the SPOT method. The antibody reactivity of cellulose-bound peptides was assayed as described above. SPOT reactivity was evaluated by scanning the membranes and measuring the spot intensities with ImageJ 1.44
(http://rsbweb.nih.gov/ij).
Western blot analysis
Western blotting was performed using cell protein lysates as described previously [49. Band intensity was analyzed with the G:BOX imaging system (Syngene,Cambridge, UK).
Cell proliferation assay
The effect of the anti-NRG1 antibody 7E3 on cell proliferation and cell viability was evaluated using luciferase activity assays and sulforhodamine B (SRB) colorimetric assays, respectively. Cells were incubated with serum-free medium for 24h and with RhNRG1β1-ECD and antibodies. unbuffered Tris base solution, and the OD 540 was read using a microplate reader. Growth inhibition was calculated based on the percentage of proliferating cells in treated samples relative to untreated cultures. All experiments were performed three times.
Cell migration (wound healing) assay
Cells were seeded in 6-well plates and grown at 37°C in RPMI medium with 10% FBS as previously described [27. Cells were incubated in serum-free medium with rhNRG1β1-ECD and/or 7E3 or IR antibody. Cell migration was observed 48h after and images captured using a Nikon TS100 microscope and an Olympus SP-510 UZ camera.
3D-growth assay
Cells were washed in PBS, trypsinized, and prepared in RPMI with 2% FCS and 20% methyl cellulose for spheroid formation in ultra-low attachment 96-well black plates. After 24h, cells were incubated with 50ng/ml of rhNRG1β1-ECD and 50-100µg/ml of 7E3 or IR antibody. After 10 days of incubation, 25µl of calcein-EthD-1 master mix was added to each well. After 30min, fluorescence was counted and cells analyzed with a Celigo Image Cytometer using the "Tumorosphere" application for spheroid area measurement (Nexcelom Bioscience, Lawrence, MA). All experiments were performed three times.
Antibody internalization
Cells were grown with serum-free medium for 24h and were then incubated or not with 50 ng/ml rhNRG11-ECD for 10min and then with 30µg/ml of anti-NRG1, -HER3, -CEA antibodies or RPMI 3D images of the tumor were manually contoured along the tumor margin throughout the 3D stack.
The tumor volume was measured using parallel segmentation in the Vevo2100 software (version 3.0, 3. RESULTS
NRG1 regulates pancreatic tumor growth in an autocrine and paracrine manner
RT-qPCR expression analysis showed NRG1 expression in 17/33 (51.5%) pancreatic tumor samples ( Figure 1A) . Then, NRG11 gene expression was assessed in five KRAS-mutated pancreatic cancer cell lines and one KRAS-wild type cell line (BxPC-3). BxPC3, CFPAC and SW1990 cells expressed NRG1, whereas HPAC, MiaPaca2 and AsPC-1 did not ( Figure 1B) . As positive control, we developed a NRG1 positive cell derived of AsPC-1 (AsPC-1-NRG1 cells). As negative control, we used normal pancreatic cells (NPC). By ELISA, we measured the concentration of NRG1 secretion in medium. This expression correlated this NRG1 mRNA expression. As previously described [23., all cell lines, with the exception of MiaPaCa-2 cells, expressed HER3, but not HER4.
NRG1 role in pancreatic tumor cell growth was supported by the finding that cell growth was higher Interestingly, we observed that CAFs isolated from pancreatic ductal adenocarcinoma (PDAC) specimens, also expressed NRG11 ( Figure 1D ). After 10 days of culture, CAFs exhibited a fibroblastlike phenotype, as shown by immunofluorescence expression of vimentin in sample CAF11, and were considered as activated, based on SMA expression ( Figure 1D ). In comparison, normal pancreatic fibroblasts (NPF) expressed vimentin, but not SMA, and therefore, were considered as not activated ( Figure 1D ). NRG1 mRNA was expressed in five of the six CAF preparations ( Figure 1E ). Conditioned medium (CM) from these CAF cultures expressed NRG1 as measured by ELISA assay and induced phosphorylation of HER3 in BxPC-3 cells ( Figure 1F) , except for the CM from CAF8 that did not express NRG1.
Altogether, these results demonstrated that NRG1 is expressed in both pancreatic tumor cells and CAFs and regulates pancreatic tumor growth in an autocrine or paracrine manner.
3.2. The NRG1-specific antibody 7E3 binds to NRG1 Ig-like domain and promotes ADCC towards pancreatic cancer cells in which NRG1 is complexed with HER3
The specific anti-NRG1 antibody 7E3 was generated by immunizing mice with recombinant human NRG11 extracellular domain (rhNRG11-ECD). 7E3 bound to NRG11-ECD, but not to the EGF domain of NRG1 and NRG1, NRG13 SMDF nor to the related growth factors EGF, GAS6, AREG and HB-EGF (Supplementary Figure 1A) . Surface plasmon resonance (SPR) analysis showed that 7E3 bound to rhNRG11-ECD with an affinity of 1.05nM (Supplementary Figure 1B) , close to that of NRG1 binding to HER3 (1.6 nM). However, 7E3 still bound to recombinant NRG1 pre-complexed with HER3-Fc with similar affinity as for NRG1 alone (Figure 2A ). This suggested that besides its ligand trapping activity, 7E3 could also be used to target HER3-bound NRG1. This was confirmed by immunofluorescence cell analysis, measuring 7E3 ability to recognize NRG1 when bound to HER3 at the cell surface of BxPC-3 cells expressing or not HER3 upon HER3 silencing (shHER3 BxPC-3 cells shLuc BxPC-3 control cells) ( Figure 2B ). The 7E3 antibody bound to rhNRG11-ECD complexed to membrane-expressed HER3 in shLuc BxPC-3, but not in shHER3 BxPC-3 cells.
Using the SPOT method, we identified the epitope recognized by 7E3 located in the IgG-like domain of NRG11 N-terminus. This explains why 7E3 still binds to NRG1 complexed to HER3, this NRG1/HER3 interaction requiring the EGF-like domain of NRG1. This also explains why 7E3 does not bind to the EGF domain of NRG1 or of NRG1, nor NRG13 SMDF which does not contain the Iglike domain (Supplementary Figure 1A) . Alanine scanning analysis ( Figure 2C ) indicated that the 154 IRISV 158 sequence in NRG1 Ig-like domain was the binding motif and residues R 155 and V 158 the main contributors.
As 7E3 can bind to NRG1 complexed to HER3, ADCC assays, were performed to test whether 7E3 could activate immune cells ( Figure 2D ). To do so, human peripheral blood mononuclear cells (hPBMC) were used as effector cells, and shHER3 or shLuc BxPC-3 cells as target cells, Coincubation of 7E3 with rhNRG11-ECD (to mimic NRG1 expressed by CAFs) strongly increased ADCC of shLuc BxPC3 cells compared to 7E3 alone. Similar results were obtained with trastuzumab (positive control) ( Figure 2D ). Upon HER3 silencing, ADCC was not induced by incubation with 7E3, with or without rhNRG11-ECD. Thus, 7E3 bound to NRG1 Ig-like domain pre complexed with HER3 favors ADCC in pancreatic cancer cells. ( Supplementary Figure 2A) . This effect was blocked by 7E3 demonstrating 7E3 inhibitory effect on NRG1 secreted by cancer cells. Moreover, 7E3 inhibited NRG1-mediated HER4 phosphorylation in IGROV-1 ovarian cancer cells (HER3-negative and HER4-positive) ( Figure 3B ).
To test whether 7E3 internalization mediated HER3 downregulation in pancreatic cancer cells, BxPC-3 cells were incubated with 7E3 and rhNRG11-ECD at different time points. Co-incubation with 7E3
and rhNRG11-ECD led to antibody binding and internalization that started at 30min and peaked at 60min at 37°C ( Figure 3C ). Conversely, antibody internalization was abrogated at 4°C. This was confirmed by immunofluorescence analysis after a 60min-incubation with fluorescein-labeled 7E3
( Figure 3C ). Moreover, co-incubation with 7E3 and rhNRG11-ECD induced HER3 downregulation in BxPC-3 cells from 10h until 48h (end of the experiment) ( Figure 3D ).
Here we demonstrated that 7E3 acts by inhibiting HER3 activity and by directly down regulating HER3 expression.
7E3 inhibits viability, growth and migration of pancreatic cancer cells
As NRG1 plays a role in cell proliferation, the viability of HPAC and BxPC-3 cells was assessed after co-incubation with 7E3 and rhNRG11-ECD, in 2D-cell monolayer cultures ( Figure 4A ). 7E3 significantly reduced cancer cell viability (between 7% and 35% of inhibition) in a dose-dependent manner. Moreover, 100 g/ml 7E3 alone also reduced by 20% cell viability of NRG1-positive BxPC-3 cells ( Supplementary Figure 2A) . The IR antibody did not affect cell viability in any of these experimental conditions. In 3D-cell cultures ( Figure 4B ), co-incubation with rhNRG11-ECD and 7E3 strongly inhibited spheroid growth by about 67% compared with rhNRG11-ECD alone, as indicated by the reduction of the calcein-positive spheroid area. In wound-healing assays ( Figure 4C ), exposure of BxPC-3 and HPAC cells to rhNRG11-ECD after wounding increased cell migration in comparison with untreated cells, resulting in the complete wound closure at 48h post-wound. Conversely, coincubation with rhNRG11-ECD and 10 or 100 g/ml of 7E3, but not with IR antibody, strongly inhibited cell migration and wound healing ( Figure 4C ).
7E3 reduces pancreatic tumor growth in mice
The in vivo efficacy of 7E3 was evaluated in mice xenografted subcutaneously with BxPC-3 cells (NRG1-positive) ( Figure 4D ). Injection of 7E3 significantly reduced tumor growth compared with the IR antibody (control) (p=0.020). As pancreatic cancer is characterized by poor vascularization, dense microenvironment and reduced drug penetration, the in vivo effect of 7E3 was also studied in an orthotopic pancreatic cancer model ( Figure 4E ). One week after injection in mice of BxPC-3-Luc cells, the pancreas bioluminescence signal (to follow cancer cell growth) was measured, and then mice were treated with 7E3 or IR antibody (control). The bioluminescence signal remained significantly lower in all 7E3-treated mice compared with controls (p=0.047) ( Figure 4E ). At day 48 post-graft, bioluminescence was still very low in 7E3-treated mice in comparison with control (p=0.0404) (supplementary Figure 2C) . These results demonstrated that 7E3 slows down the growth of NRG1positive pancreatic tumors. Inhibition of AKT and MAPK phosphorylation was observed by Western blot analysis in 7E3 treated subcutaneous tumors in contrast to control tumors ( Figure 4F ).
7E3 induces pancreatic CAF lysis in the presence of hPBMC and inhibits pancreatic cancer cell proliferation promoted by CAFs secreted NRG1
To assess 7E3 effect on pancreatic epithelial cancer cells associated with the surrounding cells, primary CAFs isolated from six human PDAC specimens ( Figure 1D ) were used. 7E3 could bind to CAFs, as indicated by immunofluorescence analysis of CAF11 and CAF12 cultures ( Figure 5A ), consistent with NRG1 expression by these CAFs (Figure 1D ). Incubation of BxPC-3 cells with CM from CAF11 and CAF12 (CAF-CM) strongly induced HER3 phosphorylation that was inhibited by 7E3, but not the IR antibody ( Figure 5B ). Similar results were obtained with CAF3, 4, 5 and 6 (Supplementary Figure 3A) . Incubation of CAF12 with hPBMC and 7E3, but not the IR antibody, induced ADCC ( Figure 5C ), albeit weakly, probably due to dynamic NRG1 cleavage at the cell surface by metalloproteinases [17. Moreover, different CAF-CMs increased BxPC-3 cell viability in 2Dmonolayer culture, compared with cells incubated with medium alone (with 1% FCS) ( Figure 5D and Supplementary Figure 3B ). Addition of 7E3, but not of the IR antibody, decreased significantly this effect (p<0.001 for CAF5, 6 and 11-CM), except in BxPC-3 cells incubated with CAF8-CM that was recovered from the NRG1-negative CAF8 culture ( Figure 1D ). Finally, bioluminescence measures in HPAC-Luc cells co-cultured with CAF11 in a 3D culture system ( Figure 5E ) showed that incubation with 7E3, but not the IR antibody, reduced HPAC-Luc cell viability in a dose-dependent manner.
7E3 inhibits BxPC-3 tumor growth in nude mice after orthotopic co-injection of BxPC-3 cells and CAFs
To reconstitute in vivo the human pancreatic tumor microenvironment, NRG1-positive BxPC-3 cells and NRG1-positive CAF11 cells (1:2 ratio) were co-xenografted in the pancreas of mice and tumor growth was followed by ultrasonography. In this orthotopic mouse model, 7E3 treatment significantly reduced the growth of reconstituted CAF stroma/BxPC-3 tumors ( Figure 6A, supplementary figure 4A) compared with controls (no treatment) (p=0.003). This result was confirmed by the finding that at day 60 (end of the experiment), the mean tumor weight was 44% lower in 7E3-treated mice than in controls (p=0.032) ( Figure 6B ). IHC analysis of tumors shown the presence of SMA positive fibroblasts (marker of activated CAF) in tumors and an increased expression of cleaved caspase 3 (in tumor cells), a marker of apoptosis, whereas KI67 index (marker of proliferation) was unchanged (Supplementary Figure 4B ) in the antibody treatment tumors vs control ( Figure 6C ). 
DISCUSSION
The 7E3 antibody blocked NRG1-dependent tumor cell growth by decreasing HER3 activity and expression level and promoting ADCC activation against tumors cells and micro-environment. This mechanism can contribute to the therapeutic effect observed in mice and can be explained by its original binding. Indeed, our antibody exhibited a high degree of specificity and affinity for NRG1 IgGlike domain, and did not prevent the NRG1 binding to HER3. This explains 7E3 ability to target NRG1 already linked to its receptor and to induce ADCC. This binding feature has never been described and is completely different from the one displayed by other anti-NRG1 antibodies, which are mostly Knowing that the epitope of 7E3 is found in murine type I and II NRG1 sequences, we can deduce that 
